Thyroid-Associated Ophthalmopathy: Clinical Features, Pathogenesis, and Management

References

• Weetman AP. Thyroid-associated eye disease: pathophysiology. Lancet 1991; 338: 25–8.
   PubMed Web of Science ®Google Scholar
• Wall JR, Bernard N, Boucher A, et al. Pathogenesis of thyroid-associated ophthalmopathy: an autoimmune disorder of the eye muscle associated with Graves' hyperthyroidism and Hashimoto's thyroiditis. Clin Immunol Immunopathol 1993; 68: 1–8.
   PubMedGoogle Scholar
• Kiljanski JI, Nebes V, Wall JR. The ocular muscle cell is a target of the immune system in endocrine ophthalmopathy. Int Arch Allergy Immunol 1995; 106: 204–12.
   PubMed Web of Science ®Google Scholar
• Salvi M, Zhang ZG, Haegert D, et al. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metab 1990; 70: 89–94.
   PubMed Web of Science ®Google Scholar
• Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993; 329: 1468–75.
   PubMed Web of Science ®Google Scholar
• Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14: 747–93.
   PubMed Web of Science ®Google Scholar
• Gunji K, De Bellis A, Li AW, et al. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab. 2000. 85: 1641.
   PubMed Web of Science ®Google Scholar
• Kubota S, Gunji K, Ackrell BA, et al. The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1998; 83: 443–7.
   PubMed Web of Science ®Google Scholar
• Bahn RS, Garrity JA, Gorman CA. Diagnosis and management of Graves' ophthalmopathy. J Clin Endocrinol Metab 1990; 71: 559–63.
   PubMed Web of Science ®Google Scholar
• Hudson HL, Levin L, Feldon SE. Graves exophthalmos unrelated to extraocular muscle enlargement. Superior rectus muscle inflammation may induce venous obstruction. Ophthalmology 1991; 98: 1495–9.
   PubMed Web of Science ®Google Scholar
• Kendall-Taylor P, Perros P. Clinical presentation of thyroid associated orbitopathy. Thyroid 1998; 8: 427–8.
   PubMedGoogle Scholar
• Salvi M, Scalise D, Stolarski C, et al. Upper eyelid retraction in the absence of other evidence for progressive ophthalmopathy is associated with eye muscle autoantibodies. Clin Immunol Immunopathol 1995; 74: 44–50.
   PubMedGoogle Scholar
• Hamed LM, Lessner AM. Fixation duress in the pathogenesis of upper eyelid retraction in thyroid orbitopathy. A prospective study. Ophthalmology 1994; 101: 1608–13.
   PubMedGoogle Scholar
• Petersen IA, Kriss JP, McDougall IR, et al. Prognostic factors in the radiotherapy of Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 1990; 19: 259–64.
   PubMed Web of Science ®Google Scholar
• Bartley GB, Fatourechi V, Kadrmas EF, et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol 1995; 120: 511–7.
   PubMed Web of Science ®Google Scholar
• Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121: 284–90.
   PubMed Web of Science ®Google Scholar
• Burch HB, Gorman CA, Bahn RS, et al. Ophthalmopathy. In: Braverman LE, Utiger RD, (ed) Werner & Ingbar's the Thyroid. 7th Ed. Pp. 536-553. Philadelphia: Lippincott-Raven, 1996.
   Google Scholar
• Forbes G, Gorman CA, Gehring D, et al. Computer analysis of orbital fat and muscle volumes in Graves ophthalmopathy. Am JNeuroradiol 1983; 4: 737–40.
   PubMed Web of Science ®Google Scholar
• Forbes G, Gorman CA, Brennan MD, et al. Ophthalmopathy of Graves' disease: computerized volume measurements of the orbital fat and muscle. Am J Neuroradiol 1986; 7: 651–6.
   PubMed Web of Science ®Google Scholar
• Tallstedt L, Lundell G, Toning O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992; 326: 1733–8.
   PubMed Web of Science ®Google Scholar
• Prummel MF, Wiersinga WM, Mourits MP, et al. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 1990; 150: 1098101.
   Google Scholar
• Wiersinga WM. Preventing Graves' ophthalmopathy. N Engl J Med 1998; 338: 121–2.
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bartalena L, Bogazzi F, et al. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh) 1989; 120: 473–8.
   PubMedGoogle Scholar
• DeGroot LJ, Gorman CA, Pinchera A, et al. Therapeutic controversies. Radiation and Graves' ophthalmopathy. J Clin Endocrinol Metab 1995; 80: 339–49.
   PubMedGoogle Scholar
• Marcocci C, Bartalena L, Bogazzi F, et al. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism. Thyroid 1992; 2: 171–8.
   PubMed Web of Science ®Google Scholar
• Winsa B, Rastad J, Akerstrom G, et al. Retrospective evaluation of subtotal and total thyroidectomy in Graves' disease with and without endocrine ophthalmopathy. Eur J Endocrinol 1995; 132: 406–12.
   PubMedGoogle Scholar
• Wall JR. Radioiodine significantly worsens Graves' ophthalmopathy. Annual meeting of the CDA/CSEM professional conference and annual meetings. Ottawa, ON, 1999.
   Google Scholar
• Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338: 73–8.
   PubMed Web of Science ®Google Scholar
• Utiger RD. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1992; 326: 1772–73.
   PubMedGoogle Scholar
• Bartalena L, Martino E, Marcocci C, et al. More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest 1989; 12: 733–7.
   PubMed Web of Science ®Google Scholar
• Tellez M, Cooper J, Edmonds C. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) 1992; 36: 291–4.
   PubMed Web of Science ®Google Scholar
• Christensen SB, Ericsson UB, Janzon L, et al. Influence of cigarette smoking on goiter formation, thyroglobulin, and thyroid hormone levels in women. J Clin Endocrinol Metab 1984; 58: 615–8.
   PubMed Web of Science ®Google Scholar
• Hegedus L, Karstrup S, Veiergang D, et al. High frequency of goitre in cigarette smokers. Clin Endocrinol (Oxf) 1985; 22: 287–92.
   PubMed Web of Science ®Google Scholar
• Perros P, Kendall TP. Pathogenetic mechanisms in thyroid-associated ophthalmopathy. J Intern Med 1992; 231: 205–11.
   PubMedGoogle Scholar
• Stenszky V, Kozma L, Balazs C, et al. The genetics of Graves' disease: HLA and disease susceptibility. J Clin Endocrinol Metab 1985; 61: 735–40.
   PubMed Web of Science ®Google Scholar
• Shields DC, Ratanachaiyavong S, McGregor AM, et al. Combined segregation and linkage analysis of Graves disease with a thyroid autoantibody diathesis. Am J Hum Genet 1994; 55: 540–54.
   PubMed Web of Science ®Google Scholar
• Frecker M, Mercer G, Skanes VM, et al. Major histocompatibility complex (MHC) factors predisposing to and protecting against Graves' eye disease. Autoimmunity 1988; 1: 307–15.
   PubMedGoogle Scholar
• Kraemer MH, Donadi EA, Tambascia MA, et al. Relationship between HLA antigens and infectious agents in contributing towards the development of Graves' disease. Immunol Invest 1998; 27: 17–29.
   PubMed Web of Science ®Google Scholar
• Frecker M, Stenszky V, Balazs C, et al. Genetic factors in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1986; 25: 479–85.
   PubMed Web of Science ®Google Scholar
• Payami H, Joe S, Farid NR, et al. Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves disease. Am J Hum Genet 1989; 45: 541–6.
   PubMed Web of Science ®Google Scholar
• Farid NR, Balazs C. The genetics of thyroid associated ophthalmopathy. Thyroid1998; 8: 407–9.
   Google Scholar
• Boehm BO, Kuhnl P, Manfras BJ, et al. HLA-DRB3 gene alleles in Caucasian patients with Graves' disease. Clin Investig 1992; 70: 956–60.
   PubMedGoogle Scholar
• Yanagawa T, Hidaka Y, Guimaraes V, et al. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 1995; 80: 41–5.
   PubMed Web of Science ®Google Scholar
• Vaidya B, Imrie H, Perros P, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet 1999; 354: 743–4.
   PubMed Web of Science ®Google Scholar
• Kotsa K, Watson PF, Weetman AP. A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin Endocrinol (Oxf) 1997; 46: 551–4.
   PubMed Web of Science ®Google Scholar
• Paschke R, Van Sande J, Parma J, et al. The TSH receptor and thyroid diseases. Baillieres Clin Endocrinol Metab 1996; 10: 9–27.
   PubMedGoogle Scholar
• de Roux N, Shields DC, Misrahi M, et al. Analysis of the thyrotropin receptor as a candidate gene in familial Graves' disease. J Clin Endocrinol Metab 1996; 81: 3483–6.
   PubMed Web of Science ®Google Scholar
• Kotsa KD, Watson PF, Weetman AP. No association between a thyrotropin receptor gene polymorphism and Graves' disease in the female population. Thyroid 1997; 7: 31–3.
   PubMedGoogle Scholar
• Bahn RS, Dutton CM, Heufelder AE, et al. A genomic point mutation in the extracellular domain of the thyrotropin receptor in patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1994; 78: 256–60.
   PubMedGoogle Scholar
• Trokel SL, Jakobiec FA. Correlation of CT scanning and pathologic features of ophthalmic Graves' disease. Ophthalmology 1981; 88: 553–64.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev 1989; 10: 366–91.
   PubMed Web of Science ®Google Scholar
• Tallstedt L, Norberg R. Immunohistochemical staining of normal and Graves' extraocular muscle. Invest Ophthalmol Vis Sci 1988; 29: 175–84.
   PubMed Web of Science ®Google Scholar
• Hufnagel TJ, Hickey WF, Cobbs WH, et al. Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease. Ophthalmology 1984; 91: 1411–9.
   PubMed Web of Science ®Google Scholar
• Kroll AJ, Kuwabara T. Dysthyroid ocular myopathy. Anatomy, histology, and electron microscopy. Arch Ophthalmol 1966; 76: 244–7.
   PubMedGoogle Scholar
• Riley FC. Orbital pathology in Graves' disease. Mayo Clin Proc 1972; 47: 975.
   Web of Science ®Google Scholar
• Heufelder AE, Bahn RS. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves' ophthalmopathy. Eur J Clin Invest 1993; 23: 10–7.
   PubMed Web of Science ®Google Scholar
• Weetman AP, Cohen S, Gatter KC, et al. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 1989; 75: 222–7.
   PubMed Web of Science ®Google Scholar
• Weetman AP. Autoimmunity in Graves' ophthalmopathy. JR Soc Med 1989; 82: 153–8.
   PubMedGoogle Scholar
• Heufelder AE, Bahn RS. Elevated expression in situ of selectin and immunoglobulin super-family type adhesion molecules in retroocular connective tissues from patients with Graves' ophthalmopathy. Clin Exp Immunol 1993; 91: 381–9.
   PubMed Web of Science ®Google Scholar
• Bottazzo GF, Pujol BR, Hanafusa T, et al. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983; 2: 1115–9.
   PubMed Web of Science ®Google Scholar
• van der Gaag R, Schmidt ED, Koornneef L. Retrobulbar histology and immunohistochemistry in endocrine ophthalmopathy. Dev Ophthalmol 1993; 25: 1–10.
   PubMedGoogle Scholar
• Kandror V, Birjukova M, Kryukova I, et al. Some immunological correlations between thyroid pathology and ophthalmopathy. Exp Clin Endocrinol 1991; 97: 212–6.
   PubMedGoogle Scholar
• Weetman AP, Fells P, Shine BT, and B cell reactivity to extraocular and skeletal muscle in Graves' ophthalmopathy. Br J Ophthalmol 1989; 73: 323–7.
   PubMed Web of Science ®Google Scholar
• Yang D, Hiromatsu Y, Hoshino T, et al. Dominant infiltration of T(H)1-type CD4+ T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy. Thyroid 1999; 9: 305–10.
   PubMed Web of Science ®Google Scholar
• Forster G, Otto E, Hansen C, et al. Analysis of orbital T cells in thyroid-associated ophthalmopathy. Clin Exp Immunol 1998; 112: 427–34.
   PubMed Web of Science ®Google Scholar
• Volpe R. Graves' hyperthyroidism and endocrine ophthalmopathy — one or two closely related diseases. Dev Ophthalmol 1993; 25: 101–11.
   PubMedGoogle Scholar
• Weetman AP. Thyroid-associated ophthalmopathy. Autoimmunity 1992; 12: 215–22.
   PubMed Web of Science ®Google Scholar
• McGregor AM. Has the target autoantigen for Graves' ophthalmopathy been found? Lancet 1998; 352: 595–6.
   PubMedGoogle Scholar
• Bahn RS. The fibroblast is the target cell in the connective tissue manifestations of Graves' disease. Int Arch Allergy Immunol 1995; 106: 213–8.
   PubMed Web of Science ®Google Scholar
• Heufelder AE. Involvement of the orbital fibroblast and TSH receptor in the pathogenesis of Graves' ophthalmopathy. Thyroid 1995; 5: 331–40.
   PubMedGoogle Scholar
• Feliciello A, Porcellini A, Ciullo I, et al. Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet 1993; 342: 337–8.
   PubMed Web of Science ®Google Scholar
• Endo T, Ohta K, Haraguchi K, et al. Cloning and functional expression of a thyrotropin receptor cDNA from rat fat cells. J Biol Chem 1995; 270: 10833–7.
   PubMed Web of Science ®Google Scholar
• Chang TC, Chang TJ, Huang YS, et al. Identification of autoantigen recognized by autoimmune ophthalmopathy sera with immunoblotting correlated with orbital computed tomography. Clin Immunol Immunopathol 1992; 65: 161–6.
   PubMedGoogle Scholar
• Wall JR, Salvi M, Bernard NF, et al. Thyroid-associated ophthalmopathy—a model for the association of organ-specific autoimmune disorders. Immunol Today 1991; 12: 150–3.
   PubMedGoogle Scholar
• Wall JR. Extrathyroidal manifestations of Graves' disease. J Clin Endocrinol Metab 1995; 80: 3427–9.
   PubMedGoogle Scholar
• Gunji K, Kubota S, Swanson J, et al. Role of the eye muscles in thyroid eye disease: identification of the principal autoantigens. Thyroid 1998; 8: 553–6.
   PubMed Web of Science ®Google Scholar
• Gunji K, Kubota S, Stolarski C, et al. A 63-kDa skeletal muscle protein associated with eye muscle inflammation in Graves' disease is identified as the calcium binding protein calsequestrin. Autoimmunity 1999; 29: 1–9.
   PubMed Web of Science ®Google Scholar
• Wu YJ, Clarke EM, Shepherd P. Prevalence and significance of antibodies reactive with eye muscle membrane antigens in sera from patients with Graves' ophthalmopathy and other thyroid and nonthyroid diseases. Thyroid 1998; 8: 167–74.
   PubMedGoogle Scholar
• Wall JR. Nature and significance of eye muscle autoantigens in endocrine ophthalmopathy. Dev Ophthalmol 1993; 25: 77–85.
   PubMedGoogle Scholar
• Kodama K, Sikorska H, Bandy DP, et al. Demonstration of a circulating autoantibody against a soluble eye-muscle antigen in Graves' ophthalmopathy. Lancet 1982; 2: 1353–6.
   PubMed Web of Science ®Google Scholar
• Dong Q, Ludgate M, Vassart G. Cloning and sequencing of a novel 64-kDa autoantigen recognized by patients with autoimmune thyroid disease. J Clin Endocrinol Metab 1991; 72: 1375–81.
   PubMed Web of Science ®Google Scholar
• Zhang ZG, Wall JR, Bernard NF. Tissue distribution and quantitation of a gene expressing a 64-kDa antigen associated with thyroid-associated ophthalmopathy. Clin Immunol Immunopathol 1996; 80: 236–44.
   PubMedGoogle Scholar
• Kromminga A, Hagel C, Arndt R, et al. Serological reactivity of recombinant 1D autoantigen and its expression in human thyroid and eye muscle tissue: a possible autoantigenic link in Graves' patients. J Clin Endocrinol Metab 1998; 83: 2817–23.
   PubMedGoogle Scholar
• Kubota S, Gunji K, Stolarski C, et al. Role of eye muscle antibody measurement in diagnosis of thyroid-associated ophthalmopathy: a laboratory update. Endocr Pract. 1998; 4: 127–132.
   PubMedGoogle Scholar
• Salvi M, Miller A, Wall JR. Human orbital tissue and thyroid membranes express a 64 kDa protein which is recognized by autoantibodies in the serum of patients with thyroid-associated ophthalmopathy. Febs Lett 1988; 232: 135–9.
   PubMed Web of Science ®Google Scholar
• Salvi M, Bernard N, Miller A et al. Prevalence of antibodies reactive with a 64-kDa eye muscle membrane antigen in thyroid-associated ophthalmopathy. Thyroid 1991; 1: 207–13.
   PubMedGoogle Scholar
• Miller A, Arthurs B, Boucher A, et al. Significance of antibodies reactive with a 64 kDa eye muscle membrane antigen in patients with thyroid autoimmunity. Thyroid 1992; 2: 197–202.
   PubMedGoogle Scholar
• Wall J, Barsouk A, Stolarski C, et al. Serum antibodies reactive with eye muscle antigens and the TSH receptor in a euthyroid subject who developed ophthalmopathy and Graves' hyper-thyroidism. Thyroid 1996; 6: 353–8.
   PubMedGoogle Scholar
• Kubota S, Gunji K, Stolarski C, et al. Reevaluation of the prevalences of serum autoantibodies reactive with “64-kDa eye muscle proteins” in patients with thyroid-associated ophthalmopathy. Thyroid 1998; 8: 175–9.
   PubMedGoogle Scholar
• Wall J, Barsouk A, Stolarski C, et al. Serum eye muscle and TSH receptor antibodies predicted the development of ophthalmopathy in a euthyroid subject with a family history of autoimmunity. Thyroid 1998; 6: 353–8.
   Google Scholar
• Gunji K, De Bellis A, Kubota S, et al. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1999; 84: 1255–62.
   PubMed Web of Science ®Google Scholar
• Paschke R, Metcalfe A, Alcalde L, et al. Presence of nonfunctional thyrotropin receptor variant transcripts in retroocular and other tissues. J Clin Endocrinol Metab 1994; 79: 1234–8.
   PubMed Web of Science ®Google Scholar
• Karlsson F, Dahlberg PA, Jansson R, et al. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Acta Endocrinol (Suppl) 1989; 121: 132141.
   Google Scholar
• Kiljanski JI, Peele K, Stachura I, et al. Antibodies against striated muscle, connective tissue and nuclear antigens in patients with thyroid-associated ophthalmopathy: should Graves' disease be considered a collagen disorder. J Endocrinol Invest 1997; 20: 585–91.
   PubMedGoogle Scholar
• Wall JR, Blanchard ME, West K, et al. Autoantibodies against the plasm membrane protein type XIII collagen are new markers of congestive ophthalmopahty. 72nd. Annual meeting of the American Thyroid Association, Portland, OR, 1999 Thyroid (Suppl) p. 50 (abstract).
   Google Scholar
• Weetman AP. Eyeing up Graves' ophthalmopathy. Mol Cell Endocrinol 1997; 126: 113–6.
   PubMedGoogle Scholar
• Burch HB, Sellitti D, Barnes SG, et al. Thyrotropin receptor antisera for the detection of immunoreactive protein species in retroocular fibroblasts obtained from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1994; 78: 1384–91.
   PubMedGoogle Scholar
• Hesse RJ. Graves exophthalmos without muscle involvement. Ophthalmology 1992; 99: 6456.
   Google Scholar
• Mengistu M, Lukes YG, Nagy EV, et al. TSH receptor gene expression in retroocular fibroblasts. J Endocrinol Invest 1994; 17: 437–41.
   PubMed Web of Science ®Google Scholar
• Haraguchi K, Shimura H, Lin L, et al. Functional expression of thyrotropin receptor in differentiated 3T3-L1 cells: a possible model cell line of extrathyroidal expression of thyrotropin receptor. Biochem Biophys Res Commun 1996; 223: 193–8.
   PubMedGoogle Scholar
• Paschke R, Vassart G, Ludgate M. Current evidence for and against the TSH receptor being the common antigen in Graves' disease and thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995; 42: 565–9.
   PubMed Web of Science ®Google Scholar
• Paschke R, Elisei R, Vassart G, et al. Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extraocular muscle. J Endocrinol Invest 1993; 16: 329–32.
   PubMedGoogle Scholar
• Francis T, Burch HB, Cai WY, et al. Lymphocytes express thyrotropin receptor-specific mRNA as detected by the PCR technique. Thyroid 1991; 1: 223–8.
   PubMedGoogle Scholar
• Wu SL, Yang CS, Wang HJ, et al. Demonstration of thyrotropin receptor mRNA in orbital fat and eye muscle tissues from patients with Graves' ophthalmopathy by in situ hybridization. J Endocrinol Invest 1999; 22: 289–95.
   PubMed Web of Science ®Google Scholar
• Sorisky A, Pardasani D, Gagnon A, et al. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab 1996; 81: 3428–31.
   PubMed Web of Science ®Google Scholar
• Marcus C, Ehren H, Bolme P, et al. Regulation of lipo lysis during the neonatal period. Importance of thyrotropin. J Clin Invest 1988; 82: 1793–7.
   PubMed Web of Science ®Google Scholar
• Mullin BR, Lee G, Ledley FD, et al. Thyrotropin interactions with human fat cell membrane preparations and the finding of soluble thyrotropin binding component. Biochem Biophys Res Commun 1976; 69: 55–62.
   PubMedGoogle Scholar
• Haraguchi K, Shimura H, Lin L, et al. Differentiation of rat preadipocytes is accompanied by expression of thyrotropin receptors. Endocrinology 1996; 137: 3200–5.
   PubMed Web of Science ®Google Scholar
• Haraguchi K, Shimura H, Kawaguchi A, et al. Effects of thyrotropin on the proliferation and differentiation of cultured rat preadipocytes. Thyroid 1999; 9: 613–9.
   PubMedGoogle Scholar
• Bahn RS, Dutton CM, Natt N, et al. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 1998; 83: 998–1002.
   PubMed Web of Science ®Google Scholar
• Valyasevi RW, Erickson DZ, Harteneck DA, et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab 1999; 84: 2557–62.
   PubMed Web of Science ®Google Scholar
• Bahn RS, Gorman CA, Woloschak GE, et al. Human retroocular fibroblasts in vitro: a model for the study of Graves' ophthalmopathy. J Clin Endocrinol Metab 1987; 65: 665–70.
   PubMed Web of Science ®Google Scholar
• Bahn RS, Dutton CM, Joba W, et al. Thyrotropin receptor expression in cultured Graves' orbital preadipocyte fibroblasts is stimulated by thyrotropin. Thyroid 1998; 8: 193–6.
   PubMed Web of Science ®Google Scholar
• Costagliola S, Rodien P, Many MC, et al. Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor. J Immunol 1998; 160: 1458–65.
   PubMed Web of Science ®Google Scholar
• Many MC, Costagliola S, Detrait M, et al. Development of an animal model of autoimmune thyroid eye disease. J Immunol 1999; 162: 4966–74.
   PubMed Web of Science ®Google Scholar
• Ludgate M, Crisp M, Lane C, et al. The thyrotropin receptor in thyroid eye disease. Thyroid 1998; 8: 411–3.
   PubMedGoogle Scholar
• Stover C, Otto E, Beyer J, et al. Humoral immunity and retrobulbar fibroblasts in endocrine ophthalmopathy. Acta Endocrinol (Copenh) 1992; 126: 394–8.
   PubMedGoogle Scholar
• Weetman AP. The role of T lymphocytes in thyroid-associated ophthalmopathy. Autoimmunity 1992; 13: 69–73.
   PubMed Web of Science ®Google Scholar
• Arnold K, Tandon N, McIntosh RS, et al. T cell responses to orbital antigens in thyroid-associated ophthalmopathy. Clin Exp Immunol 1994; 96: 329–34.
   PubMed Web of Science ®Google Scholar
• Stover C, Otto E, Beyer J, et al. Cellular immunity and retrobulbar fibroblasts in Graves' ophthalmopathy. Thyroid 1994; 4: 161–5.
   PubMed Web of Science ®Google Scholar
• Natt N, Bahn RS. Cytokines in the evolution of Graves' ophthalmopathy. Autoimmunity 1997; 26: 129–36.
   PubMed Web of Science ®Google Scholar
• Pappa A, Calder V, Ajjan R, et al. Analysis of extraocular muscle-infiltrating T cells in thyroid-associated ophthalmopathy (TAO). Clin Exp Immunol 1997; 109: 362–9
   PubMed Web of Science ®Google Scholar
• Bahn RS. Cytokines in thyroid eye disease: potential for anticytokine therapy. Thyroid 1998; 8: 415–8.
   PubMedGoogle Scholar
• Hansson HA, Petruson B, Skotter A. Somatomedin C in pathogenesis of malignant exophthalmos of endophthalmos of endocrine origin. Lancet 1986; 1: 218–9.
   PubMed Web of Science ®Google Scholar
• Grubeck-Loebenstein B, Trieb K, Sztankay A, et al. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. J Clin Invest 1994; 93: 2738–43.
   PubMed Web of Science ®Google Scholar
• McLachlan SM, Prummel MF Rapoport B. Cell-mediated or humoral immunity in Graves' ophthalmopathy Profiles of T-cell cytokines amplified by polymerase chain reaction from orbital tissue. J Clin Endocrinol Metab 1994; 78: 1070–4.
   PubMed Web of Science ®Google Scholar
• de Carli M, D'Elios MM, Mariotti S, et al. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab 1993; 77: 1120–4.
   PubMed Web of Science ®Google Scholar
• Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 2000; 85: 776–80.
   PubMed Web of Science ®Google Scholar
• Del Prete GF, Tiri A, de Carli M, et al. High potential to tumor necrosis factor alpha (TNF-alpha) production of thyroid infiltrating T lymphocytes in Hashimoto's thyroiditis: a peculiar feature of destructive thyroid autoimmunity. Autoimmunity 1989; 4: 267–76.
   PubMedGoogle Scholar
• Bednarczuk T, Kiljanski J, Mrowiec T, et al. T cell interactions with extracellular matrix proteins in patients with thyroid-associated ophthalmopathy. Autoimmunity 1998; 27: 221–30.
   PubMed Web of Science ®Google Scholar
• Bahn RS, Heufelder AE. Orbital connective tissue in endocrine ophthalmopathy. Dev Ophthalmol 1993; 25: 46–57.
   PubMedGoogle Scholar
• Otto E, Krimmer U, Stover C, et al. Eye muscle cells in endocrine ophthalmopathy. Dev Ophthalmol 1993; 25: 93–100.
   PubMedGoogle Scholar
• Smith TJ, Bahn RS, Gorman CA, et al. Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts. J Clin Endocrinol Metab 1991; 72: 1169–71.
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Bahn RS. Graves' immunoglobulins and cytokines stimulate the expression of intercellular adhesion molecule-1 (ICAM-1) in cultured Graves' orbital fibroblasts. Eur J Clin Invest 1992; 22: 529–37.
   PubMed Web of Science ®Google Scholar
• Klett ZG, Elner SG, Elner VM. Differential expression of immunoreactive HLA-DR and ICAM-1 in human cultured orbital fibroblasts and orbital tissue. Ophthal Plast Reconstr Surg 1996; 12: 153–62.
   PubMedGoogle Scholar
• Pappa A, Calder V, Fells P, et al. Adhesion molecule expression in vivo on extraocular muscles (EOM) in thyroid associated ophthalmopathy. Clin Exp Immunol 1997; 108: 30913.
   Google Scholar
• Heufelder AE, Scriba PC. Characterization of adhesion receptors on cultured microvascular endothelial cells derived from the retroorbital connective tissue of patients with Graves' ophthalmopathy. Eur J Endocrinol 1996; 134: 51–60.
   PubMedGoogle Scholar
• Aruffo A, Stamenkovic I, Melnick M, et al. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303–13.
   PubMed Web of Science ®Google Scholar
• Bednarczuk T, Stolarski C, Pawlik E, et al. Autoantibodies reactive with extracellular matrix proteins in patients with thyroid-associated ophthalmopathy. Thyroid 1999; 9: 289–95.
   PubMedGoogle Scholar
• Heufelder AE, Herterich S, Ernst G, et al. Analysis of retroorbital T cell antigen receptor variable region gene usage in patients with Graves' ophthalmopathy. Eur J Endocrinol 1995; 132: 266–77.
   PubMed Web of Science ®Google Scholar
• Heufelder AE. T-cell restriction in thyroid eye disease. Thyroid 1998; 8: 419–22.
   PubMedGoogle Scholar
• Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449–56.
   PubMed Web of Science ®Google Scholar
• Koga M, Hiromatsu Y, Jimi A, et al. Possible involvement of Fas-mediated apoptosis in eye muscle tissue from patients with thyroid-associated ophthalmopathy. Thyroid 1998; 8: 3118.
   Google Scholar
• Kawakami A, Eguchi K, Matsuoka N, et al. Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Endocrinology 1996; 137: 3163–9.
   PubMed Web of Science ®Google Scholar
• Ciampolillo A, Marini V, Mirakian R, et al. Retrovirus-like sequences in Graves' disease: implications for human autoimmunity. Lancet 1989; 1: 1096–100.
   PubMed Web of Science ®Google Scholar
• Wick G, Grubeck-Loebenstein B, Trieb K, et al. Human foamy virus antigens in thyroid tissue of Graves' disease patients. Int Arch Allergy Immunol 1992; 99: 153–6.
   PubMed Web of Science ®Google Scholar
• Wick G, Trieb K, Aguzzi A, et al. Possible role of human foamy virus in Graves' disease. Intervirology 1993; 35: 101–7.
   PubMed Web of Science ®Google Scholar
• Hiromatsu Y, Tanaka K, Ishisaka N, et al. Human histocompatibility leukocyte antigen-DR and heat shock protein-70 expression in eye muscle tissue in thyroid-associated ophthalmopa-thy. J Clin Endocrinol Metab 1995; 80: 685–91.
   PubMedGoogle Scholar
• Kahaly G, Hansen C, Felke B, et al. Immunohistochemical staining of retrobulbar adipose tissue in Graves' ophthalmopathy. Clin Immunol Immunopathol 1994; 73: 5362.
   Google Scholar
• Heufelder AE, Smith TJ, Gorman CA, et al. Increased induction of HLA-DR by interferon-gamma in cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial dermopathy. J Clin Endocrinol Metab 1991; 73: 307–13.
   PubMed Web of Science ®Google Scholar
• Kahaly G, Forster G, Hansen C. Glycosaminoglycans in thyroid eye disease. Thyroid 1998; 8: 429–32.
   PubMedGoogle Scholar
• McGregor AM. Immunoendocrine interactions and autoimmunity. N Engl J Med 1990; 322: 1739–41.
   PubMedGoogle Scholar
• Wight TN, Heinegard DK, Hascall VC. Proteoglycans, structure and function. In: Hay ED (ed) Cell Biology of Extracellular Matrix, 2nd ed. Pp 45-78. New York: Plenum Press, 1991.
   Google Scholar
• Imai Y, Odajima R, Inoue Y,et al. Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts of Graves' ophthalmopathy in culture. Acta Endocrinol (Copenh) 1992; 126: 541–52.
   PubMedGoogle Scholar
• Heufelder AE, Bahn RS. Modulation of Graves' orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists. Invest Ophthalmol Vis Sci 1994; 35: 120–7.
   PubMed Web of Science ®Google Scholar
• Korducki JM, Loftus SJ, Bahn RS. Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts. Invest Ophthalmol Vis Sci 1992; 33: 2037–42.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bahn RS, Gorman CA. Hormonal regulation of hyaluronate synthesis in cultured human fibroblasts: evidence for differences between retroocular and dermal fibroblasts. J Clin Endocrinol Metab 1989; 69: 1019–23.
   PubMed Web of Science ®Google Scholar
• Arnold K, Metcalfe R, Weetman AP. Immunoglobulin A class fibroblast antibodies in patients with Graves' disease and pretibial myxedema. J Clin Endocrinol Metab 1995; 80: 3430–7.
   PubMedGoogle Scholar
• Bahn RS, Heufelder AE. Retroocular fibroblasts: important effector cells in Graves' ophthalmopathy. Thyroid 1992; 2: 89–94.
   PubMed Web of Science ®Google Scholar
• Hansen C, Rouhi R, Forster G, et al. Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy. J Clin Endocrinol Metab 1999; 84: 1409–13
   PubMed Web of Science ®Google Scholar
• Kahaly G, Schuler M, Sewell AC, et al. Urinary glycosaminoglycans in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1990; 33: 35–44.
   PubMed Web of Science ®Google Scholar
• Kaback LA, Smith TJ. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 1999; 84: 4079–84.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Wang HS, Evans CH. Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol 1995; 268: C382–8.
   PubMed Web of Science ®Google Scholar
• Shyjan AM, Heldin P, Butcher EC, et al. Functional cloning of the cDNA for a human hyaluronan synthase. J Biol Chem 1996; 271: 23395–9.
   PubMedGoogle Scholar
• Cao HJ, Wang HS, Zhang Y, et al. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endop-eroxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem 1998; 273: 29615–25.
   PubMedGoogle Scholar
• Sempowski GD, Rozenblit J, Smith TJ, et al. Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol 1998; 274: C707–14.
   PubMed Web of Science ®Google Scholar
• Cao HJ, Smith TJ. Leukoregulin upregulation of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts. Am J Physiol 1999; 277: C1075–85.
   Google Scholar
• Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12: 881–922.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Parikh SJ. HMC-1 mast cells activate human orbital fibroblasts in coculture: evidence for up-regulation of prostaglandin E2 and hyaluronan synthesis. Endocrinology 1999; 140: 3518–25.
   PubMed Web of Science ®Google Scholar
• Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1994; 40: 67–72.
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Goellner JR, Wenzel BE, et al. Immunohistochemical detection and localization of a 72-kilodalton heat shock protein in autoimmune thyroid disease. J Clin Endocrinol Metab 1992; 74: 724–31.
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Wenzel BE, Bahn RS. Cell surface localization of a 72-kilodalton heat shock protein in retroocular fibroblasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1992; 74: 732–6.
   PubMed Web of Science ®Google Scholar
• McGregor AM. Heat shock proteins and autoimmune thyroid disease; too hot to handle. J Clin Endocrinol Metab 1992; 74: 720–3.
   PubMedGoogle Scholar
• Heufelder AE, Wenzel BE, Gorman CA, et al. Detection, cellular localization, and modulation of heat shock proteins in cultured fibroblasts from patients with extrathyroidal manifestations of Graves' disease. J Clin Endocrinol Metab 1991; 73: 739–45.
   PubMed Web of Science ®Google Scholar
• Lindquist S. The heat-shock response. Annu Rev Biochem 1986; 55: 1151–91.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Heat shock proteins and the immune response. Immunol Today 1990; 11: 129–36.
   PubMedGoogle Scholar
• Heufelder AE, Wenzel BE, Bahn RS. Glucocorticoids modulate the synthesis and expression of a 72 kDa heat shock protein in cultured Graves' retroocular fibroblasts. Acta Endocrinologica 1993, 128: 41–50.
   PubMedGoogle Scholar
• Yeatts RP. Graves' ophthalmopathy. Med Clin North Am 1995; 79: 195–209.
   PubMed Web of Science ®Google Scholar
• Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopa-thy. Clin Endocrinol (Oxf) 1995; 42: 45–50.
   PubMed Web of Science ®Google Scholar
• Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989; 321: 1353–9.
   PubMed Web of Science ®Google Scholar
• Nagayama Y, Izumi M, Kiriyama T, et al. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol (Copenh) 1987; 116: 513–8.
   PubMedGoogle Scholar
• Wengrowicz S, Puig-Domingo M, Rodriguez-Alvarez F, et al. Clinical and immunological changes in patients with severe thyroid-associated ophthalmopathy treated with high dose i.v. methylpredonisolone pulse therapy followed by oral predonisolone. Endocrinologia 1999; 46: 117–22.
   Google Scholar
• Wilson WB, Prochoda M. Radiotherapy for thyroid orbitopathy. Effects on extraocular muscle balance. Arch Ophthalmol 1995; 113: 1420–5.
   PubMedGoogle Scholar
• Nakahara H, Noguchi S, Murakami N, et al. Graves ophthalmopathy: MR evaluation of 10-Gy versus 24-Gy irradiation combined with systemic corticosteroids. Radiology 1995; 196: 857–62.
   PubMedGoogle Scholar
• Kelly W, Longson D, Smithard D, et al. An evaluation of plasma exchange for Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1983; 18: 485–93.
   PubMed Web of Science ®Google Scholar
• Neugebauer A, Nishino K, Neugebauer P, et al. Effects of bilateral orbital decompression by an endoscopic endonasal approach in dysthyroid orbitopathy. Br J Ophthalmol 1996; 80: 5862.
   Google Scholar
• Liao CL, Kao SC, Chang TC, et al. Staged operation for Graves' ophthalmopathy. J Formos Med Assoc 1996; 95: 680–5.
   PubMedGoogle Scholar
• Trokel S, Kazim M, Moore S. Orbital fat removal. Decompression for Graves orbitopathy. Ophthalmology 1993; 100: 674–82.
   PubMed Web of Science ®Google Scholar
• Durak I, Durak H, Ergin M, et al. Somatostatin receptors in the orbits. Clin Nucl Med 1995; 20: 237–42.
   PubMed Web of Science ®Google Scholar
• Wiersinga WM, Gerding MN, Prummel MF, et al. Octreotide scintigraphy in thyroidal and orbital Graves' disease. Thyroid 1998; 8: 433–6.
   PubMedGoogle Scholar
• Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibro-blasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1996; 81: 44952.
   Google Scholar
• Balazs C, Kiss H, Farid NR. Inhibitory effect of pentoxifylline on HLA-DR expression and glycosaminoglycan synthesis by retrobulbar fibroblasts. Horm Metab Res 1998; 30: 496–9.
   PubMed Web of Science ®Google Scholar
• Heufelder AE. Retro-orbital autoimmunity. Baillieres Clin Endocrinol Metab 1997; 11: 499520.
   Google Scholar